Despite our enhanced understanding of the molecular pathogenesis of IDH-mutant glioma, however, effective treatments have yet to be developed and clinicians remain reliant on maximal safe surgical resection and various chemotherapeutic agents and radiation treatments to prolong survival (7). This evidence concerns the gene IDH2 and central nervous system cancer.